ClinicalTrials.gg
CompletedNCT01062451Updated Apr 26, 2022

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

A Phase 1 interventional study of Perindopril and Placebo in Methamphetamine Dependence, Methamphetamine Abuse and Substance Abuse, sponsored by Baylor College of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-04-26.

Sponsored by Baylor College of Medicine · Phase 1, Interventional, and Other

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.

Read the detailed description

Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to perindopril but should lack the U-shaped dose response. Like perindopril, candesartan is used for hypertension. Whereas perindopril reduces the synthesis of angiotensin II, candesartan blocks angiotensin II receptors.

02

Conditions studied

  • Methamphetamine Dependence
  • Methamphetamine Abuse
  • Substance Abuse

Keywords

  • Methamphetamine
  • Perindopril
  • Candesartan
  • Angiotensin receptor blocker
  • ACE Inhibitor
03

In context

Substance-Related Disorders

2,181 studies on the registry are indexed under Substance-Related Disorders; 399 are open to participants now.

This study's enrollment of 80 is below the median of 108 across 1,770 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 111 are open to participants now.

Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be English-speaking non-treatment-seeking volunteers.
  • Be between 18-55 years of age.
  • Meet DSM-IV TR criteria for MA dependence.
  • Have a self-reported history of using MA by the IV route.
  • Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 85-150mm Hg systolic and 45-90mm Hg diastolic.
  • Have a breathalyzer test indicating an undetectable blood alcohol level upon admission.
  • Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) \< 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) \< 2 x the upper limit of normal.
  • Have a baseline ECG that demonstrates normal sinus rhythm, normal conduction, and no clinically significant arrhythmias.
  • Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician and the principal investigator. Adult ADHD is allowable, as long as symptoms do not interfere with participation.
  • Demonstrate MA-induced craving, evidenced by a change in "desire" greater than 20 on a 0 to 100mm VAS.
  • Weigh between 60 and 100kg.

Exclusion criteria

Exclusion Criteria:

  • Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure.
  • Have neurological or psychiatric disorders, such as: episode of major depression within the past 2 years as assessed by MINI; lifetime history of schizophrenia, other psychotic illness, or bipolar illness as assessed by MINI; current organic brain disease or dementia assessed by clinical interview; history of or any current psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months and/or current suicidal ideation/plan; history of psychosis occurring in the absence of current MA use.
  • Meet DSM-IV criteria for abuse or dependence on alcohol or other drugs, except for nicotine or marijuana.
  • Have evidence of clinically significant heart disease or hypertension, as determined by the PI.
  • Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease.
  • Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication.
  • Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, and weekly throughout the study.
  • Have any history of asthma, chronic coughing and wheezing, or other chronic respiratory illnesses.
  • Currently use alpha or beta agonists, theophylline, or other sympathomimetics.
  • Have any other illness, condition, or use of medications, which in the opinion of the P.I. and/or the admitting physician would preclude safe and/or successful completion of the study.

Rationale for Other Exclusion Criteria:

Participants with asthma or who take medications for asthma are excluded due to potential adverse interactions between treatment medications and MA. Participants who use alcohol heavily are excluded due to the potential of withdrawal symptoms in the hospital. Participants with active HIV disease are excluded to avoid potentially exacerbating their underlying illness and because of potential drug interactions. Reliable methods of birth are required to prevent pregnancy, and the use of frequent urine pregnancy tests will exclude women who become pregnant. This is important because perindopril can produce significant birth defects.

Criteria for Discontinuation Following Initiation:

Participants will be discharged if they have a positive breath test indicating use of alcohol or a urine test indicating use of illicit use of drugs while on the study, if they do not comply with study procedures, or if they do not tolerate MA.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Perindopril

    Drug: Perindopril

  • Active comparator
    Candesartan

    Drug: Candesartan

Interventions

  • 8 mg taken orally from days 0 through 7.

    Also known as: Aceon

  • DrugPlacebo

    Placebo treatment daily.

    Also known as: Sugar pill

  • 16 mg taken orally from days 0 through 7.

    Also known as: Atacand

06

What researchers measure

Primary outcomes

  1. The dose-dependent effects of an ace inhibitor or an angiotensin receptor blocker on MA- and cue-induced craving and on the reinforcing effects of MA indexed by MA self-administration.

    Participants demonstrating MA-induced craving will then be randomized to active study medication (perindopril or candesartan) or matched placebo (day 0). Over days 4 to 7 a variety of procedures will be completed to assess effects of MA and cue-induced craving. On day 7, reinforcing effects will be assessed will be assessed using self-administration procedures.

    Time frame: 7 days

Secondary outcomes

  1. The effects of an ace inhibitor or an angiotensin receptor blocker on subjective measures.

    On days 3 and 5, participants will receive sample doses of 15mg or 30mg MA paired with a dose of placebo saline separated by 180 min, with the order of administration randomized. Subjective effects of MA will be assessed using visual analogue scales (VAS).

    Time frame: 7 days

07

Study locations

1 site
  • Michael E. DeBakey VA Medical Center
    Houston, Texas 77030, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01062451
Responsible party
Christopher Verrico (Associate Professor, Psychiatry Research, Baylor College of Medicine) — Principal investigator
First posted
Feb 4, 2010
Start date
May 2009
Primary completion
Nov 20, 2013
Completion
Nov 20, 2013
Last update
Apr 26, 2022

Study contacts

Thomas F Newton, M.D.
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Perindopril · Candesartan

Start the discussion